Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Feb;62(2):146–150. doi: 10.1136/ard.62.2.146

Predictors of end stage lung disease in a cohort of patients with scleroderma

C Morgan 1, C Knight 1, M Lunt 1, C Black 1, A Silman 1
PMCID: PMC1754426  PMID: 12525384

Abstract

Objectives: To estimate the incidence of severe lung disease in patients with scleroderma and identify the combination(s) of features present at first assessment which would be useful to predict future risk of severe lung disease.

Methods: Data were analysed on 561 patients with disease onset occurring on or after 1 January 1982 and disease duration of less than five years before the first assessment. Detailed clinical and laboratory assessments were undertaken at the initial visit. End stage lung disease was defined as pulmonary hypertension requiring continuous ambulatory iloprost, or pulmonary fibrosis requiring continuous oxygen, or death from a scleroderma related lung disease. Patient status was determined at 31 December 1997. The best subset of predictors was identified by Cox regression analysis.

Results: In all, 24 patients reached end stage lung disease. The cumulative incidences were 4%, 6%, and 12% at five, seven, and 14 years respectively. As expected, the lung function tests at baseline, including being in the lowest third of either diffusing lung capacity (hazard ratio (HR) = 18.2, 95% confidence interval (CI) 3.5 to 93.8) or of forced vital capacity (HR=4.1, 95% CI 1.1 to 15.2), were highly significant predictors of end stage lung disease. Interestingly, apart from the presence of proteinuria, none of the other baseline variables, including the extent of skin disease and serological markers, were predictive of severe lung disease.

Conclusion: End stage lung disease was infrequent in this large cohort, but the cumulative incidence increased importantly with time. The risk can be predicted from baseline assessment of pulmonary function. In particular, those with normal pulmonary function at baseline are at very low risk.

Full Text

The Full Text of this article is available as a PDF (131.4 KB).

Figure 1.

Figure 1

Open in a new tab

Kaplan-Meier curve indicating end stage lung disease events from the first assessment.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman R. D., Medsger T. A., Jr, Bloch D. A., Michel B. A. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum. 1991 Apr;34(4):403–413. doi: 10.1002/art.1780340405. [DOI] [PubMed] [Google Scholar]
  2. Barnett A. J., Miller M. H., Littlejohn G. O. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol. 1988 Feb;15(2):276–283. [PubMed] [Google Scholar]
  3. Bryan C., Howard Y., Brennan P., Black C., Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol. 1996 Nov;35(11):1122–1126. doi: 10.1093/rheumatology/35.11.1122. [DOI] [PubMed] [Google Scholar]
  4. Bryan C., Knight C., Black C. M., Silman A. J. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum. 1999 Dec;42(12):2660–2665. doi: 10.1002/1529-0131(199912)42:12<2660::AID-ANR23>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  5. Bulpitt K. J., Clements P. J., Lachenbruch P. A., Paulus H. E., Peter J. B., Agopian M. S., Singer J. Z., Steen V. D., Clegg D. O., Ziminski C. M. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med. 1993 Apr 15;118(8):602–609. doi: 10.7326/0003-4819-118-8-199304150-00005. [DOI] [PubMed] [Google Scholar]
  6. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20-1989. A 33-year-old woman with exertional dyspnea and Raynaud's phenomenon. N Engl J Med. 1989 May 18;320(20):1333–1340. doi: 10.1056/NEJM198905183202008. [DOI] [PubMed] [Google Scholar]
  7. Clements P. J., Lachenbruch P. A., Seibold J. R., Zee B., Steen V. D., Brennan P., Silman A. J., Allegar N., Varga J., Massa M. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol. 1993 Nov;20(11):1892–1896. [PubMed] [Google Scholar]
  8. Jacobsen S., Halberg P., Ullman S., Høier-Madsen M., Petersen J., Mortensen J., Wiik A. A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clin Rheumatol. 1997 Jun;16(4):384–390. doi: 10.1007/BF02242456. [DOI] [PubMed] [Google Scholar]
  9. LeRoy E. C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T. A., Jr, Rowell N., Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988 Feb;15(2):202–205. [PubMed] [Google Scholar]
  10. LeRoy E. C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T. A., Jr, Rowell N., Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988 Feb;15(2):202–205. [PubMed] [Google Scholar]
  11. Lee P., Langevitz P., Alderdice C. A., Aubrey M., Baer P. A., Baron M., Buskila D., Dutz J. P., Khostanteen I., Piper S. Mortality in systemic sclerosis (scleroderma). Q J Med. 1992 Feb;82(298):139–148. [PubMed] [Google Scholar]
  12. Morelli S., Barbieri C., Sgreccia A., Ferrante L., Pittoni V., Conti F., Gualdi G., Polettini E., Carlesimo O. A., Calvieri S. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol. 1997 Jan;24(1):81–85. [PubMed] [Google Scholar]
  13. Owens G. R., Fino G. J., Herbert D. L., Steen V. D., Medsger T. A., Jr, Pennock B. E., Cottrell J. J., Rodnan G. P., Rogers R. M. Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. Chest. 1983 Nov;84(5):546–550. doi: 10.1378/chest.84.5.546. [DOI] [PubMed] [Google Scholar]
  14. Peters-Golden M., Wise R. A., Schneider P., Hochberg M., Stevens M. B., Wigley F. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine (Baltimore) 1984 Jul;63(4):221–231. doi: 10.1097/00005792-198407000-00004. [DOI] [PubMed] [Google Scholar]
  15. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980 May;23(5):581–590. doi: 10.1002/art.1780230510. [DOI] [PubMed] [Google Scholar]
  16. Silver R. M., Miller K. S. Lung involvement in systemic sclerosis. Rheum Dis Clin North Am. 1990 Feb;16(1):199–216. [PubMed] [Google Scholar]
  17. Steen V. D., Conte C., Owens G. R., Medsger T. A., Jr Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994 Sep;37(9):1283–1289. doi: 10.1002/art.1780370903. [DOI] [PubMed] [Google Scholar]
  18. Steen V. D., Graham G., Conte C., Owens G., Medsger T. A., Jr Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum. 1992 Jul;35(7):765–770. doi: 10.1002/art.1780350709. [DOI] [PubMed] [Google Scholar]
  19. Steen V. D., Owens G. R., Fino G. J., Rodnan G. P., Medsger T. A., Jr Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum. 1985 Jul;28(7):759–767. doi: 10.1002/art.1780280706. [DOI] [PubMed] [Google Scholar]
  20. Ungerer R. G., Tashkin D. P., Furst D., Clements P. J., Gong H., Jr, Bein M., Smith J. W., Roberts N., Cabeen W. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med. 1983 Jul;75(1):65–74. doi: 10.1016/0002-9343(83)91169-5. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES